MarketCapTrends
DNLI
Denali Therapeutics Inc. (DNLI)
NASDAQ · Healthcare

Denali Therapeutics Inc. Shareholder Equity 2016–2025

Denali Therapeutics Inc. annual/quarterly shareholder equity history from 2017 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Denali Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 1.01B, a 17.56% decrease year-over-year.
  • Denali Therapeutics Inc. shareholder equity for 2025 were 1.01B, a 17.56% decrease from 2024.
  • Denali Therapeutics Inc. shareholder equity for 2024 were 1.23B, a 19.28% increase from 2023.
  • Denali Therapeutics Inc. shareholder equity for 2023 were 1.03B, a 1.10% decrease from 2022.
  • Denali Therapeutics Inc. shareholder equity for 2022 were 1.04B.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Denali Therapeutics Inc. Annual Shareholder Equity (Millions of US $)
2025$1,014
2024$1,230
2023$1,031
2022$1,042
2021$962
2020$1,151
2019$395
2018$547
2017$466
Denali Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$1,014
2024-12-31$1,230
2023-12-31$1,031
2022-12-31$1,042
2021-12-31$962
2020-12-31$1,151
2019-12-31$395
2018-12-31$547
2017-12-31$466

Denali Therapeutics Inc. Shareholder Equity — FAQ

Denali Therapeutics Inc. (DNLI) shareholder equity over the last 10 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see DNLI's shareholder equity history?

The chart and table above show Denali Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.